11 results for 'Molmed'
MolMed a new patent on its anticancer NGR-hTNF

MolMed S.p.A. (MLM.MI) announces today receipt of the official notification from the European Patent Office of the decision to grant a patent covering the therapeutic use of its investigational anticancer drug NGR-hTNF at low doses. The grant will take effect on the 2nd of October 2013, when it will be published in the European Patent Bulletin.
The administration of NGR-hTNF at low doses is being investigated in a vast clinical program, including a Phase III trial in malignant pleural mesothelioma and several Phase II trials in colorectal, lung, liver and ovarian cancer, and... (more)
Tags: molmed, ngr-htnf, ngr-htnf patent office
« previous 1 2 next »